All
Upadacitinib Induces Long-Term Remission in Refractory Bullous Pemphigoid: A Case Report
June 19th 2025Upadacitinib’s targeted inhibition of JAK1 offers a novel strategy for managing bullous pemphigoid, and in rare, treatment-resistant cases, may induce sustained remission following immune modulation.